0.1978
price down icon0.55%   -0.0011
 
loading

Cel-Sci Corp. (CVM) 最新ニュース

pulisher
Mar 31, 2025

CVM stock touches 52-week low at $0.23 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

CVM stock touches 52-week low at $0.23 amid sharp annual decline - Investing.com Australia

Mar 31, 2025
pulisher
Mar 29, 2025

CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World

Mar 29, 2025
pulisher
Mar 24, 2025

Breakthrough: New Cancer Drug Delivers 95% Quality of Life Improvement for Head & Neck Patients - Stock Titan

Mar 24, 2025
pulisher
Mar 21, 2025

CVM stock touches 52-week low at $0.26 amid sharp annual decline - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

CVM stock touches 52-week low at $0.26 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Cel-Sci Corp (CVM) Volatility Hits 12.01%: What Good Investors Need To Be Aware Of - Stocks Register

Mar 21, 2025
pulisher
Mar 18, 2025

CEL-SCI announces closing of $2.5 million offering -March 18, 2025 at 05:23 pm EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

CEL-SCI Secures $2.5M Funding: Major Push for FDA-Designated Cancer Immunotherapy - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 18, 2025
pulisher
Mar 17, 2025

CEL-SCI Secures Critical Funding for FDA-Approved Head & Neck Cancer Treatment Study - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

CEL-SCI advances in head and neck cancer treatment study - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

CEL-SCI advances in head and neck cancer treatment study By Investing.com - Investing.com UK

Mar 17, 2025
pulisher
Mar 17, 2025

CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine - Yahoo Finance

Mar 17, 2025
pulisher
Mar 15, 2025

Cel-Sci Corp (CVM) Recovers 5.85% From Low: Are We There Yet? - Stocks Register

Mar 15, 2025
pulisher
Mar 14, 2025

Major Breakthrough: JAMA Study Shows Multikine Triples Survival Rates in Head and Neck Cancer - StockTitan

Mar 14, 2025
pulisher
Mar 13, 2025

CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com - Defense World

Mar 13, 2025
pulisher
Mar 10, 2025

CVM stock touches 52-week low at $0.31 amid sharp annual decline - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

CVM stock touches 52-week low at $0.31 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 05, 2025

4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX - DRP Journal

Mar 05, 2025
pulisher
Mar 05, 2025

CEL-SCI Announces That NYSE MKT Granted an Extension to Regain Compliance - AOL

Mar 05, 2025
pulisher
Feb 28, 2025

CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline - Investing.com Australia

Feb 28, 2025
pulisher
Feb 27, 2025

CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline By Investing.com - Investing.com South Africa

Feb 27, 2025
pulisher
Feb 26, 2025

CEL-SCI (NYSE:CVM) Now Covered by StockNews.com - Armenian Reporter

Feb 26, 2025
pulisher
Feb 20, 2025

CEL-SCI advances Multikine study for head and neck cancer - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

CEL-SCI advances Multikine study for head and neck cancer By Investing.com - Investing.com UK

Feb 20, 2025
pulisher
Feb 20, 2025

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial -February 20, 2025 at 08:06 am EST - Marketscreener.com

Feb 20, 2025
pulisher
Feb 20, 2025

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial - Yahoo Finance

Feb 20, 2025
pulisher
Feb 19, 2025

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks - BioSpace

Feb 19, 2025
pulisher
Feb 18, 2025

StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Armenian Reporter

Feb 18, 2025
pulisher
Feb 18, 2025

Breakthrough Cancer Treatment Shows 73% Survival Rate: CEL-SCI's Latest Clinical Milestone - Stock Titan

Feb 18, 2025
pulisher
Feb 17, 2025

CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com - Defense World

Feb 17, 2025
pulisher
Feb 15, 2025

Cel-Sci: Fiscal Q1 Earnings Snapshot - mySA

Feb 15, 2025
pulisher
Feb 14, 2025

Cel-Sci: Fiscal Q1 Earnings Snapshot -February 14, 2025 at 04:25 pm EST - Marketscreener.com

Feb 14, 2025
pulisher
Feb 10, 2025

CVM: Fiscal Year 2024 Results - Research Tree

Feb 10, 2025
pulisher
Feb 03, 2025

LD Micro 360 Companies Set to Present this Week - ACCESS Newswire

Feb 03, 2025
pulisher
Jan 27, 2025

Personal Finance - Business Wire

Jan 27, 2025
pulisher
Jan 21, 2025

Short Interest in DoubleLine Income Solutions Fund (NYSE:DSL) Increases By 8.7% - Defense World

Jan 21, 2025
pulisher
Jan 20, 2025

Have A Relaxing Holiday Season - MENAFN.COM

Jan 20, 2025
pulisher
Jan 18, 2025

Cantex Mine Development (CVE:CD) Stock Price Up 9.5% – Should You Buy? - Defense World

Jan 18, 2025
pulisher
Jan 14, 2025

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer - Yahoo Finance

Jan 14, 2025
pulisher
Jan 13, 2025

Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews

Jan 13, 2025
pulisher
Jan 09, 2025

CVM stock touches 52-week low at $0.37 amid sharp annual decline - Investing.com Nigeria

Jan 09, 2025
$66.10
price down icon 2.65%
$73.33
price down icon 0.15%
$31.60
price up icon 0.06%
$18.91
price down icon 11.53%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 7.93%
大文字化:     |  ボリューム (24 時間):